Enhancing antitumor immune responses: Intracellular peptide delivery and identification of MHC class II-restricted tumor antigens

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

The importance of T-cell-mediated antitumor immunity has been demonstrated in both animal models and human cancer therapy. The identification of major histocompatibility complex (MHC) class I-restricted tumor antigens has generated a resurgence of interest in immunotherapy for cancer. However, recent studies suggest that therapeutic strategies that have mainly focused on the use of CD8+ T cells (and MHC class I-restricted tumor antigens) may not be effective in eliminating cancer cells in patients. Novel strategies have been developed for enhancing T-cell responses against cancer by prolonging antigen presentation of dendritic cells to T cells and the inclusion of MHC class II-restricted tumor antigens. identification of MHC class II-restricted tumor antigens, which are capable of stimulating CD4+ T cells, not only aids our understanding of the host immune responses against cancer antigens, but also provides opportunities for developing effective cancer vaccines.

Original languageEnglish (US)
Pages (from-to)65-80
Number of pages16
JournalImmunological Reviews
Volume188
DOIs
StatePublished - Oct 2002

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Enhancing antitumor immune responses: Intracellular peptide delivery and identification of MHC class II-restricted tumor antigens'. Together they form a unique fingerprint.

Cite this